Work

251P Body mass index as a predictive factor for efficacy of taxane-based chemotherapy in early breast cancer patients

Year: 2023

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.09.448

Authors: J.A. García-Sáenz, G. Spera, M.A. Pollán, B. Bermejo, M. Ruiz Borrego, A. Chan, M. Martin Jimenez, A.L. Guerrero Zotano, L. Calvo-Martinez, A. Rodríguez-Lescure, A. Arcusa Lanza, L.I. Chap, J.P. Crown, V. Bee-Munteanu, M. Casas, O. Polonio, D. Slamon

Institutions: Hospital Clínico San Carlos, GEICAM – Spanish Breast Cancer Group, Translational Research in Oncology, Instituto de Salud Carlos III, Centro Nacional de Epidemiología, Hospital Clínico Universitario de Valencia, Hospital Universitario Virgen del Rocío, Curtin University, Hospital General Universitario Gregorio Marañón, Centro de Investigación Biomédica en Red de Cáncer, Fundación Instituto Valenciano de Oncología, Complexo Hospitalario Universitario A Coruña, Hospital General Universitario de Elche, Hospital Terrassa, Consorci Sanitari de Terrassa, Beverly Hills Cancer Center, St. Vincent's University Hospital, University of California, Los Angeles

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: AstraZeneca, Novartis, American Society of Clinical Oncology, Roche España, National Institute for Health and Care Research, European Commission, Innovation and Technology Commission, Sociedad Española de Oncología Médica

OpenAlex ID: W4387808939

FWCI:

Cites:

Cited by:

Related to: 10